Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2016
Exchange: NASDAQ
Website: intelliatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/23/2024 | $136.00 → $32.00 | Buy → Neutral | Goldman |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 4/13/2023 | $66.00 | Buy | Canaccord Genuity |
| 3/21/2023 | $54.00 | Outperform | Bernstein |
| 3/14/2023 | $54.00 → $57.00 | Market Perform → Outperform | BMO Capital Markets |
| 2/1/2023 | $67.00 | Overweight | Cantor Fitzgerald |
| 1/24/2023 | $48.00 → $39.00 | Sell → Neutral | Citigroup |
| 1/19/2023 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 10/11/2022 | $84.00 | Overweight | Morgan Stanley |
| 9/21/2022 | $85.00 | Overweight | JP Morgan |
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
3 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
3 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
10-Q - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
S-8 - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-endStrong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific SessionsActively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE) Reported positive results from the Phase 2 study supporting NTLA-2002's potential to be a fun
Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ET CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November. Third Quarter 2024 Earnings – November 7, at 8 a.m. ETIntellia will present its third quarter 2024 financial results and operational highlights. To join the call, U.S. callers shoul
Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyOn track to initiate the Phase 3 study of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy by year-endPlan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 Expect to dose the first patient in the Phase 1/2 study of N
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available t
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to review of IND application; expect to initiate the study by year-end Plan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 On track to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) in 2H 2024Will present long-term follow-up data from the NTLA-2002 Phase 1 study on June 2 and expect to report topline results from Phase 2 in mid-2024On track t
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available throug
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024Expect to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) in 2H24Plan to present new clinical data in 2024 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies, including NTLA-2002 Phase 2 results Published positive interim results from the Phase 1 study of NTLA-2002 in the New England Journal of MedicineOn track to dose the first patient in the Phase 1 study of NTLA-3001, an in vivo gene insertion candidate for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lu
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call wi
FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNITUDE pivotal Phase 3 trial in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy by year-end Clinical data presented from over 60 patients with ATTR amyloidosis demonstrated consistent, deep and durable serum TTR reduction after a single dose of NTLA-2001; greater than 90% median serum TTR reduction On track to complete enrollment of the NTLA-2002 Phase 2 study for the treatment of hereditary angioedema (HAE) in Q4 2023 Plan to submit a Clinical Trial Application (CTA) in Q1 2024 for NTLA-3001, an in vivo insertion candidate in devel
New interim NTLA-2001 clinical data to be presented at the 4th International ATTR Amyloidosis Meeting on November 2; data to include safety and both absolute and percent change in serum TTR reduction from cardiomyopathy and polyneuropathy arms of the studyIntellia management to discuss latest NTLA-2001 data and share additional information about the upcoming Phase 3 study design at Q3 earnings webcast on November 9 at 8 a.m. ET CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced two upc
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study by year-endStrong patient enrollment continues in the MAGNITUDE Phase 3 study of nex-z for ATTR amyloidosis with cardiomyopathy, tracking ahead of plans Plan to present new clinical data from the ongoing nex-z Phase 1 study at upcoming 2024 American Heart Association Scientific SessionsActively screening patients in the HAELO Phase 3 study of NTLA-2002 for hereditary angioedema (HAE) Reported positive results from the Phase 2 study supporting NTLA-2002's potential to be a fun
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on November 1, 2024 it awarded inducement grants to ten new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for 73,459 shares of Intellia's common stock, with one-third of such RSUs vesting on November 1, 2025, 2026, and 2027. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Inte
Third quarter 2024 financial results – November 7, at 8 a.m. ETNew clinical data from the Phase 1 study of nexiguran ziclumeran (nex-z) for the treatment of transthyretin (ATTR) amyloidosis – November 16, at 11 a.m. CT / 12 p.m. ET CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it will be hosting two virtual investor events in November. Third Quarter 2024 Earnings – November 7, at 8 a.m. ETIntellia will present its third quarter 2024 financial results and operational highlights. To join the call, U.S. callers shoul
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do
- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia's second in vivo candidate to enter late-stage clinical development from its modular gene editing platform CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the initiation of HAELO, a global, pivotal Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a wholly owned investigational in vivo CRISPR-based gene editing th
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded inducement grants to nine new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for 54,944 shares of Intellia's common stock, with one-third of such RSUs vesting on October 1, 2025, 2026 and 2027. All equity vesting is subject to each employee's continued service as an employee of, or other service provider to, Intellia t
New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR amyloidosis CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z, also known as NTLA-2001) will be presented in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18 in Ch
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigat
Goldman downgraded Intellia Therapeutics from Buy to Neutral and set a new price target of $32.00 from $136.00 previously
Wolfe Research initiated coverage of Intellia Therapeutics with a rating of Peer Perform
Canaccord Genuity initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $66.00
Bernstein initiated coverage of Intellia Therapeutics with a rating of Outperform and set a new price target of $54.00
BMO Capital Markets upgraded Intellia Therapeutics from Market Perform to Outperform and set a new price target of $57.00 from $54.00 previously
Cantor Fitzgerald initiated coverage of Intellia Therapeutics with a rating of Overweight and set a new price target of $67.00
Citigroup upgraded Intellia Therapeutics from Sell to Neutral and set a new price target of $39.00 from $48.00 previously
JMP Securities downgraded Intellia Therapeutics from Mkt Outperform to Mkt Perform
Morgan Stanley initiated coverage of Intellia Therapeutics with a rating of Overweight and set a new price target of $84.00
JP Morgan initiated coverage of Intellia Therapeutics with a rating of Overweight and set a new price target of $85.00
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company’s impressive second-quarter delivery numbers. The Tesla Trade Ark Invest reduced its stake in Tesla across its ARK Innovation ETF (NYSE:ARKK), selling 13,213 shares. This transaction came as a surprise, given that Tesla’s shares had recently soared 10.20% on Tuesday, marking the best intraday session since late April. Notably, on Tuesday, Ark Invest sold Tesla shares worth $14.5 million. The boost was primarily driven by the Elon Musk-led company’s second-quarter performance. Tesla reported 443,956 delive
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Technologies Inc (NYSE:PLTR). The Tesla Trade Ark Invest reduced its stake in Tesla across two of its ETFs — ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). The firm sold 56,425 and 6,442 shares respectively, the transaction was valued at $14.54 million. On Tuesday, Tesla shares closed 10.2% higher at $231.26, driven higher by the second-quarter delivery report of the company. The numbers came ahead of the consensus estimate. This move comes despite Wood’s
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. These prominent trades were part of a series of transactions carried out by Ark’s various ETFs. The ROKU Trade ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW) bought 127,540 shares in Roku Inc. The ARKK fund acquired 106,420 shares, while the ARKW fund added 21,120 shares. The transaction amounted to $7.3 million. On Wednesday, Roku shares closed 4.6% higher at $57.16 in the regular session. Notably, Wood’s firm purchased $5.3 million worth of Roku shares a day earlier. These moves come amidst Roku
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. Mr. Dulac is a highly accomplished biotechnology business leader and joins Intellia with more than 20 years of combined finance, business development and corporate strategy experience. Most recently, Mr. Dulac served as CFO of Fate Therapeutics. Prior to that role, Mr. Dulac spent numerous years at Ce
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28 in the three patients who previously received the lowest dose in the Phase 1 dose-escalation study55 mg follow-on dose was well tolerated across all patientsWhile redosing is not planned for the NTLA-2001 program in transthyretin (ATTR) amyloidosis, a redosing option could be an important advantage of Intellia's non-viral, lipid nanoparticle (LNP)-based delivery platform for future investigational therapies where a target additive effect is desired
Cantor Fitzgerald analyst Rick Bienkowski reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and maintains $65 price target.
Analysts' ratings for Intellia Therapeutics (NASDAQ:NTLA) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.0, a high estimate of $120.00, and a low estimate of $29.00. Observing a downward trend, the current av
Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $120 price target.
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectivelyEight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002's potential to be a functional cure for hereditary angioedema (HAE)NTLA-2002 demonstrated an encouraging safety and tolerability profileData published in The New England Journal of Medicine and will be presented at the 2024 ACAAI Scientific Meeting Actively screening patients in the global pivotal Phase 3 HAELO study evaluating the 50 mg do
- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced a new date for its upcoming investor webcast to review the data from the Phase 2 study of NTLA-2002. The webcast will now be held on Thursday, October 24 at 8:30 a.m. ET. The Company had previously announced the investor webcast would be held on on Monday, October 28, 2024. There are no changes to the planned oral presentation at the 2024 American College of A
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on Monday, October 28, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigat
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. Mr. Dulac is a highly accomplished biotechnology business leader and joins Intellia with more than 20 years of combined finance, business development and corporate strategy experience. Most recently, Mr. Dulac served as CFO of Fate Therapeutics. Pr
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. "We are very pleased to welcome Brian to our board of directors. Brian's extensive global commercialization experience, coupled with his track record of success leading rare disease product launches, will be invaluable to Intellia as we commercialize our first CRISPR-based gene editing therapies for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean reduction in monthly HAE attack rate, with an average follow-up of over 20 months across all patients 100% of patients who discontinued prophylaxis treatment after NTLA-2002 remain free of chronic prophylaxis treatmentFavorable safety and tolerability profile observed at all dose levels In
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-upIntellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Val
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023. "Working with the team at Intellia and seeing the company's transformation from an idea to a leader in genome editing has been one of the most exciting journeys in my career," said Jean-François Formela, M.D. "I am confident this is just the beginning for John and his team. I can't wait to see Intellia's next chapter and how they will transfor
CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of the audit committee and will succeed Caroline Dorsa as chair of the audit committee upon her retirement from the board. Ms. Dorsa is retiring from Intellia's board, effective June 15, 2023, as a result of her appointment as chair of Biogen's board of directors. "Bill's extensive track record as an experienced financial and business leader makes him a
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)
SC 13G/A - Intellia Therapeutics, Inc. (0001652130) (Subject)